Cover Image

Erratum to "C-Reactive Protein Levels and Plaque Regression with Evolocumab: Insights From GLAGOV" [American Journal of Preventive Cardiology 3C (2020) 100091]

Saved in:

Bibliographic Details
Main Authors:	Adam J. Nelson (Author), Rishi Puri (Author), Danielle M. Brennan (Author), Todd J. Anderson (Author), Leslie Cho (Author), Christie M. Ballantyne (Author), John JP. Kastelein (Author), Wolfgang Koenig (Author), Helina Kassahun (Author), Ransi M. Somaratne (Author), Scott M. Wasserman (Author), Steven E. Nissen (Author), Stephen J. Nicholls (Author)
Format:	Book
Published:	Elsevier, 2021-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

C-reactive protein levels and plaque regression with evolocumab: Insights from GLAGOV
by: Adam J. Nelson, et al.
Published: (2020)

HbA1c, Coronary atheroma progression and cardiovascular outcomes
by: Iryna Dykun, et al.
Published: (2022)

Retargeting the management of hypercholesterolemia – focus on evolocumab
by: Colletti A, et al.
Published: (2016)

Profile of evolocumab and its potential in the treatment of hyperlipidemia
by: Cicero AF, et al.
Published: (2015)

Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study
by: Vladimír Blaha MUDr, CSc, et al.
Published: (2023)

Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review
by: Nashmil Ghadimi, et al.
Published: (2024)

FDA Has Approved Evolocumab for Theatment of Familial Hypercholesterolemia in Children
by: article Editorial
Published: (2021)

Evolocumab to reduce cardiovascular events: results of the (FOURIER) multinational trial
by: Syed Raza Shah, et al.
Published: (2017)

Clinical utility of evolocumab in the management of hyperlipidemia: patient selection and follow-up
by: Dixon DL, et al.
Published: (2017)

Clinical Evaluation Of Evolocumab For The Treatment Of Homozygous Familial Hypercholesterolemia In Chinese Patients
by: Huang CC, et al.
Published: (2019)

An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors
by: Hye Duck Choi, et al.
Published: (2023)

Adverse Reactions to Evolocumab: Analysis of Real-World Data from EudraVigilance
by: Fabrizio Calapai, et al.
Published: (2024)

Real-World safety and effectiveness of evolocumab in primary hypercholesterolemia and mixed dyslipidemia in Saudi Arabia
by: Abdulaali R. Almutairi, et al.
Published: (2024)

Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial
by: Ikaro Breder, et al.
Published: (2020)

A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects
by: Liu C, et al.
Published: (2019)

Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years*
by: Borislav Borissov, et al.
Published: (2017)

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective
by: Nkuize M, et al.
Published: (2016)

Exploring the Cost-Utility of a Biomarker Predicting Persistent Severe Acute Kidney Injury: The Case of C-C Motif Chemokine Ligand 14 (CCL14)
by: Echeverri J, et al.
Published: (2024)

Treatment with PCSK9 Inhibitor Evolocumab Improves Vascular Oxidative Stress and Arterial Stiffness in Hypercholesterolemic Patients with High Cardiovascular Risk
by: Alessia Silla, et al.
Published: (2023)

Influence of Vitamin C on Lymphocytes: An Overview
by: Gwendolyn N. Y. van Gorkom, et al.
Published: (2018)

A Letter to the Viscount Palmerston, M.P. &c. &c. &c. on the Monitorial System of Harrow School
by: Vaughan, C. J. (Charles John), 1816-1897

C.A. Nothardbiblioteek
by: J. Swart
Published: (1988)

Comparison of the C-mediating killing activity and C-activating properties of mouse monoclonal and polyclonal antibodies against Trypanosoma cruzi
by: T. L. Kipnis, et al.
Published: (1992)

Does Evolocumab, as a PCSK9 Inhibitor, Ameliorate the Lipid Profile in Familial Hypercholesterolemia Patients? A Meta-Analysis of Randomized Controlled Trials
by: Seyyed Majid Eslami, et al.
Published: (2017)

Effect of evolocumab on the progression of intraplaque neovascularization of the carotid based on contrast-enhanced ultrasonography (EPIC study): A prospective single-arm, open-label study
by: Ju Chen, et al.
Published: (2023)

O17 Eliminate Hepatitis C Partnership: clinical site scoping
by: E. Wong, et al.
Published: (2017)

Mitochondrial Encephalopathy and Cytochrome C
by: J Gordon Millichap
Published: (1997)

Characterisation of <it>CYP2C8</it>, <it>CYP2C9 </it>and <it>CYP2C19 </it>polymorphisms in a Ghanaian population
by: Dodoo Alexander NO, et al.
Published: (2009)

O4 Outcomes of treatment for hepatitis C virus infection in the prison setting
by: T. Papaluca, et al.
Published: (2017)

Provider Workforce Assessment in a Rural Hepatitis C Epidemic
by: Ryan P. Westergaard, et al.
Published: (2015)

Cost-effectiveness analysis of using atorvastatin, simvastatin, ezetimibe, alirocumab, evolocumab, inclisiran in adults with very high cardiovascular risk under the preferential drug provision program
by: T. O. Bessonova, et al.
Published: (2023)

O6 Incidence of hepatitis C virus infection in two maximum-security prisons in New South Wales, Australia: the StoP-C study
by: B. Hajarizadeh, et al.
Published: (2017)

The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist
by: Xaria X. Li, et al.
Published: (2021)

P17 The impact of hepatitis C-related uncertainty on self-reported stress in people who inject drugs living with hepatitis C
by: S. Goutzamanis, et al.
Published: (2017)

Judocus J.C.A. Crabeels
by: Ijsewijn, J.
Published: (1981)

Immunogenicity and protective efficacy against Salmonella C2-C3 infection in mice immunized with a glycoconjugate of S. Newport Core-O polysaccharide linked to the homologous serovar FliC protein
by: Ofir Schuster, et al.
Published: (2019)

C-ing the damage of sepsis
by: Kirsty M. Hooper
Published: (2023)

Vitamin C deficiency mimicking inflammatory bone disease of the hand
by: Emily J. Liebling, et al.
Published: (2020)

Niemann-Pick Disease Type C
by: J Gordon Millichap
Published: (1989)

Leukotriene C4-Synthesis Deficiency
by: J Gordon Millichap
Published: (1998)